Insmed (INSM) is a publicly traded Healthcare sector company. As of July 5, 2026, INSM trades at $111.60 with a market cap of $24.19B and a P/E ratio of -19.44. INSM moved +4.30% today. Year to date, INSM is -35.90%; over the trailing twelve months it is +13.60%. Its 52-week range spans $60.40 to $212.75. Analyst consensus is strong buy with an average price target of $199.89. Rallies surfaces INSM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Insmed Appoints Samuele Butera to Lead Respiratory, Drive BRINSUPRI Launch: Insmed has named Samuele Butera as Senior Vice President and General Manager of its Global Respiratory Therapeutic Area, reporting directly to CEO Will Lewis and joining the Executive Committee. Butera will lead the launch of BRINSUPRI, pursue ARIKAYCE label expansion and oversee the broad TPIP development program.
| Metric | Value |
|---|---|
| Price | $111.60 |
| Market Cap | $24.19B |
| P/E Ratio | -19.44 |
| EPS | $-5.74 |
| Dividend Yield | 0.00% |
| 52-Week High | $212.75 |
| 52-Week Low | $60.40 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $819.56M |
| Net Income | $-1.18B |
| Gross Margin | 81.81% |
19 analysts cover INSM: 0 strong buy, 19 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $199.89.